Synthesis and biological evaluation of nitrate-oleanolic acid hybrids as inhibitors of HepG2 cell apoptosis

Yaoxue Xuebao

Volumn 45, Issue 12, 2010, Pages 1516-1522

  Chen, Li ^a,b   Shang, Juan ^b   Wang, Zhi Feng ^c   Zhang, Yi Hua ^a   Tian, Ji De ^d  

^a Center of Drug Discovery   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c Tianjin HanKang Medicinal and Biological Technology Co Ltd   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti Fas mediated HepG2 cell apoptosis; Nitrate; NO; Oleanolic acid

Indexed keywords

FAS ANTIBODY; NITRATE OLEANOLIC ACID; OLEANOLIC ACID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTIOXIDANTS; APOPTOSIS; HEP G2 CELLS; HUMANS; NITRATES; NITRIC OXIDE; NITRIC OXIDE DONORS; OLEANOLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; URSODEOXYCHOLIC ACID;

EID: 78650657016     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Liu J. Pharmacology of oleanolic acid and ursolic acid [J]. J Ethnopharmacol, 1995, 49: 57-68.
2. Chen YJ, Liu J, Yang XL, et al. Oleanolic acid nanosuspensions: preparation, in vitro characterization and enhanced hepatoprotective effect [J]. J Pharm Pharmacol, 2005, 57: 59-64.
3. Liu Y, Hartley DP, Liu J. Protection against carbon tetrachloride hepatotoxicity by oleanolic acid is not mediated through metallothionein [J]. Toxicol Lett, 1998, 95: 77-85.
4. Liu J, Liu Y, Madhu C, et al. Protective effects of oleanolic acid on acetaminophen-induced hepatotoxicity in mice [J]. J Pharmacol Exp Ther, 1993, 266: 1607-1613.
5. Kim KA, Lee JS, Park HJ, et al. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes [J]. Life Sei, 2004, 74: 2769-2779.
6. Moneada S, Higgs A, Furchgott R. International union of pharmacology nomenclature in nitric oxide research [J]. Pharmacol Rev, 1997, 49: 137-142.
7. Brunori M, Giufre A, Sarti P, et al. Nitric oxide and cellular respiration [J]. Cell Mol Life Sci, 1999, 56: 549-557.
8. Zhang YH, Tian JD, Peng SX. Targeting of nitric oxidedonor and related drugs [J]. Acta Pharm Sin 2006, 41: 481-486.
9. Xu W, Liu LZ, Loizidou M, et al. The role of nitric oxide in cancer [J]. Cell Res, 2002, 12: 311-320.
10. Wink DA, Mitchell JB. Nitric oxide and cancer: an introduction [J]. Free Radie Biol Med, 2003, 34: 951-954.
11. Fiorucci S, Antonelli E, Morelli O, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension [J]. Proc Natl Acad Sei USA, 2001, 98: 8897-8902.
12. Del Soldato P. (NicOx SA). Synthesis, activity and formulation of steroidal compounds for treatment of oxidative stress/or endothelial dysfunction: WO, 0061604 [P]. 2000-10-19.
13. Ouazzani-Chahdi A, Elimadi A, Chabli A, et al. Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity [J]. Can J Physiol Pharm, 2007, 85: 233-242.
14. Chen L, Zhang YH, Kong XW, et al. Synthesis and biological evaluation of nitric oxide-releasing derivatives of oleanolic acid as inhibitors of HepG2 cell apoptosis [J]. Bioorg Med Chem Lett, 2007, 17: 2979-2982.
15. Fiorucci S, Mencarelli A, Palazzetti B, et al. An NO derivative of ursodeoxycholic acid protects against Fas-mediates liver injury by inhibiting caspase activity [J]. Proc Natl Acad Sei USA, 2001, 98: 2652-2657.
16. Chen L, Zhang YH, Kong XW, et al. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid [J]. J Med Chem, 2008, 51: 4834-4838.